SLC5A2 and Hypertension: Subgroup analysis revealed that the relationship between dulaglutide/semaglutide use and the higher risk of UACR increase remained consistent in patients aged younger than 60 years, male patients, patients with hypertension, patients without heart failure, patients using ARBs, biguanides, and statins, and patients not using SGLT2 inhibitors.